CoChat

The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Brain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4–69.3; P = 1.3 × 10−7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awac210

Cites

Statistics

Figures

Figure 1 Distribution of early onset DEE versus Dravet syndrome SCN1A variants. Transmembrane voltage-gated sodium channel NaV1.1 protein structure in side view with central pore region and pore-loop located at the top (extracellular). Inactivation sites (S4–5 and D3–4 linkers) are located at the bottom (intracellular). (A) Early onset DEE missense variants are illustrated in blue. (B) Dravet syndrome missense variants are illustrated in red. Early onset DEE variants cluster in regions of channel inactivation (S4–5 and D3–4 linkers) whereas Dravet syndrome variants are frequently located in pore regions (S5–6) (OR = 17.8; CI = 5.4–69.3; P = 1.3 × 10−7).
Figure 1 Distribution of early onset DEE versus Dravet syndrome SCN1A variants. Transmembrane voltage-gated sodium channel NaV1.1 protein structure in side view with central pore region and pore-loop located at the top (extracellular). Inactivation sites (S4–5 and D3–4 linkers) are located at the bottom (intracellular). (A) Early onset DEE missense variants are illustrated in blue. (B) Dravet syndrome missense variants are illustrated in red. Early onset DEE variants cluster in regions of channel inactivation (S4–5 and D3–4 linkers) whereas Dravet syndrome variants are frequently located in pore regions (S5–6) (OR = 17.8; CI = 5.4–69.3; P = 1.3 × 10−7).CC BY-NC · PubMed Central
Figure 2 Features of arthrogryposis in affected individuals. (A and B) (Patient 4) Contractures in both feet and upper limbs. Right humerus is posteriorly dislocated and left shoulder dysplastic. There are contractures in elbows, wrists and fingers. Ankles are mobile, but a vertical talus can be palpitated. Vertical talus was treated with repeated casting and Achilles tenotomy during infancy. Congenital scoliosis has been treated by prolonged plaster casting/corset and hip subluxation has been corrected surgically. (C and D) (Patient 3) Bilateral elbow contractures. (E) (Patient 1) Hand and finger contractures.
Figure 2 Features of arthrogryposis in affected individuals. (A and B) (Patient 4) Contractures in both feet and upper limbs. Right humerus is posteriorly dislocated and left shoulder dysplastic. There are contractures in elbows, wrists and fingers. Ankles are mobile, but a vertical talus can be palpitated. Vertical talus was treated with repeated casting and Achilles tenotomy during infancy. Congenital scoliosis has been treated by prolonged plaster casting/corset and hip subluxation has been corrected surgically. (C and D) (Patient 3) Bilateral elbow contractures. (E) (Patient 1) Hand and finger contractures.CC BY-NC · PubMed Central
Figure 3 2D representation of GOF variant phenotypes across the SCN1A protein. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and segments S5–6 the pore region. Individual missense variants are displayed as different coloured circles according to phenotype: Pink denotes NDEEMA, brown denotes EIDEE/MD, amber denotes DEE and blue denotes FHM3. Functionally studied variants are framed in red.
Figure 3 2D representation of GOF variant phenotypes across the SCN1A protein. The alpha subunit consists of four homologous domains (D1–4) each formed of six transmembrane segments (S1–S6). Segment 4 represents the voltage sensor and segments S5–6 the pore region. Individual missense variants are displayed as different coloured circles according to phenotype: Pink denotes NDEEMA, brown denotes EIDEE/MD, amber denotes DEE and blue denotes FHM3. Functionally studied variants are framed in red.CC BY-NC · PubMed Central
Figure 4 3D representation of GOF SCN1A variants. 3D SCN1A protein structure in side (top left) and bottom view (bottom left and right—enlarged). Individual missense variants are displayed as different coloured circles according to phenotype. Pink denotes NDEEMA, brown denotes EIDEE/MD, amber denotes DEE and blue denotes FHM3. Functionally studied variants are framed in red. NDEEMA variants are more frequently observed in the S4–5 linker regions compared to FHM3 variants that are clustered in the D3–4 linker region (n = 24; z = −3.8; r = 0.81; P = 8.2 × 10−5).
Figure 4 3D representation of GOF SCN1A variants. 3D SCN1A protein structure in side (top left) and bottom view (bottom left and right—enlarged). Individual missense variants are displayed as different coloured circles according to phenotype. Pink denotes NDEEMA, brown denotes EIDEE/MD, amber denotes DEE and blue denotes FHM3. Functionally studied variants are framed in red. NDEEMA variants are more frequently observed in the S4–5 linker regions compared to FHM3 variants that are clustered in the D3–4 linker region (n = 24; z = −3.8; r = 0.81; P = 8.2 × 10−5).CC BY-NC · PubMed Central
Figure 5 Effects of p.I236V, p.R1636Q, p.I1498M and p.I1498T on voltage-dependent properties of the hNav1.1 channel. Representative whole-cell Na+ current families for hNav1.1-WT. (A) hNav1.1-I236V, (B) hNav1.1-R1636Q, (C) hNav1.1-I1498T, (D and E) hNav1.1-I1498M, recorded with 100-ms-long depolarizing voltage steps from −80 to +60 mV in 5 mV increments from a holding potential of −100 mV. Scale bars = 1 nA, 2 ms. (F) Maximal current density calculated for cells transfected with the WT or the mutants. (G) Mean voltage dependence of activation, lines are mean Boltzmann fits. (H) Mean voltage dependence of fast inactivation, lines are mean Boltzmann fits. Comparison of mean normalized currents elicited with a 150-ms-long depolarizing step to −10 mV from a holding potential of −100 mV. Data are shown as mean ± SEM. *P < 0.05; ****P < 0.0001.
Figure 5 Effects of p.I236V, p.R1636Q, p.I1498M and p.I1498T on voltage-dependent properties of the hNav1.1 channel. Representative whole-cell Na+ current families for hNav1.1-WT. (A) hNav1.1-I236V, (B) hNav1.1-R1636Q, (C) hNav1.1-I1498T, (D and E) hNav1.1-I1498M, recorded with 100-ms-long depolarizing voltage steps from −80 to +60 mV in 5 mV increments from a holding potential of −100 mV. Scale bars = 1 nA, 2 ms. (F) Maximal current density calculated for cells transfected with the WT or the mutants. (G) Mean voltage dependence of activation, lines are mean Boltzmann fits. (H) Mean voltage dependence of fast inactivation, lines are mean Boltzmann fits. Comparison of mean normalized currents elicited with a 150-ms-long depolarizing step to −10 mV from a holding potential of −100 mV. Data are shown as mean ± SEM. *P < 0.05; ****P < 0.0001.CC BY-NC · PubMed Central
Figure 6 Effects on kinetic properties and persistent current. (A) hNav1.1-WT (black) and hNav1.1-I236V (red), (B) hNav1.1 (black) and hNav1.1-R1636Q (blue), (C) hNav1.1 (black) and hNav1.1-I1498T (light green), (D) hNav1.1-WT (black) and hNav1.1-I1498M (dark green). Scale bar = 10 ms. The left insets show a 6-ms window of the current traces to compare the current decay and the right insets show the traces between 73.5 and 78.5 ms to compare INap. (E) Time constant (τ in ms) of the current decay at −10 mV (single exponential fits at the indicated potentials). (F) Quantification of persistent current between 73.5 and 78.5 ms of the 150-ms-long depolarizing step. (G) Kinetics of recovery from fast inactivation at −80 mV and (H) time constant (τ in ms) of recovery obtained from the exponential fit of the recovery curves. Data are shown as mean ± SEM.
Figure 6 Effects on kinetic properties and persistent current. (A) hNav1.1-WT (black) and hNav1.1-I236V (red), (B) hNav1.1 (black) and hNav1.1-R1636Q (blue), (C) hNav1.1 (black) and hNav1.1-I1498T (light green), (D) hNav1.1-WT (black) and hNav1.1-I1498M (dark green). Scale bar = 10 ms. The left insets show a 6-ms window of the current traces to compare the current decay and the right insets show the traces between 73.5 and 78.5 ms to compare INap. (E) Time constant (τ in ms) of the current decay at −10 mV (single exponential fits at the indicated potentials). (F) Quantification of persistent current between 73.5 and 78.5 ms of the 150-ms-long depolarizing step. (G) Kinetics of recovery from fast inactivation at −80 mV and (H) time constant (τ in ms) of recovery obtained from the exponential fit of the recovery curves. Data are shown as mean ± SEM.CC BY-NC · PubMed Central
Figure 7 Comparison of the functional effects of epilepsy and FHM3 NaV1.1 variants. The modifications in the studied functional parameters are summarized with radar plots for the variants investigated and for three additional FHM3 variants (Q1489K, L1649Q and L1670W) that we previously investigated.32–34 To compare meaningful biological modifications, we displayed fold changes in current or conductance in comparison with WT hNaV1.1 for each of the functional parameters that we considered. Thus, values >1 are GOF, values <1 are LOF. CD = maximal current density; VD Act = voltage dependence of activation expressed as fold change in normalized conductance at Va; VD Ina = voltage dependence of inactivation expressed as fold change in normalized conductance at Vh; I at t 50% act (−10 mV) = activation kinetics expressed as fold changes in the current elicited by a −10 mV voltage step at t corresponding to 50% Imax of WT hNaV1.1; I @ 1 ms = kinetics of current decay quantified as fold changes in the current recorded 1 ms after the beginning of a voltage step to −10 mV; Ipers = persistent current; I @ 5 ms rec = kinetics of recovery from fast inactivation expressed as fold changes in current after 5 ms of recovery at −80 mV. KDFI = kinetics of development of fast inactivation. Holding potential was −100 mV for all the conditions. Slope factors of activation and inactivation were not included because their modifications do not directly induce net gain or LOF effects.
Figure 7 Comparison of the functional effects of epilepsy and FHM3 NaV1.1 variants. The modifications in the studied functional parameters are summarized with radar plots for the variants investigated and for three additional FHM3 variants (Q1489K, L1649Q and L1670W) that we previously investigated.32–34 To compare meaningful biological modifications, we displayed fold changes in current or conductance in comparison with WT hNaV1.1 for each of the functional parameters that we considered. Thus, values >1 are GOF, values <1 are LOF. CD = maximal current density; VD Act = voltage dependence of activation expressed as fold change in normalized conductance at Va; VD Ina = voltage dependence of inactivation expressed as fold change in normalized conductance at Vh; I at t 50% act (−10 mV) = activation kinetics expressed as fold changes in the current elicited by a −10 mV voltage step at t corresponding to 50% Imax of WT hNaV1.1; I @ 1 ms = kinetics of current decay quantified as fold changes in the current recorded 1 ms after the beginning of a voltage step to −10 mV; Ipers = persistent current; I @ 5 ms rec = kinetics of recovery from fast inactivation expressed as fold changes in current after 5 ms of recovery at −80 mV. KDFI = kinetics of development of fast inactivation. Holding potential was −100 mV for all the conditions. Slope factors of activation and inactivation were not included because their modifications do not directly induce net gain or LOF effects.CC BY-NC · PubMed Central
Figure 8 Overall effect of the variants evaluated with action potential-clamp experiments. Action Na+ currents (expressed as mean of conductance, error bars are not shown for clarity) recorded using as voltage stimulus an action potential discharge (A) recorded in a neuron in neocortical slices for (B) hNav1.1-WT, (C) hNav1.1-I236V, (D) hNav1.1-R1636Q, (E) hNav1.1-I1498T and (F) hNav1.1-I1498M. Scale bar = 20 ms. (G) Comparison of the current density of the first action current. (H) Comparison of the current density of the mean of the three last action currents. Data are shown as mean ± SEM.
Figure 8 Overall effect of the variants evaluated with action potential-clamp experiments. Action Na+ currents (expressed as mean of conductance, error bars are not shown for clarity) recorded using as voltage stimulus an action potential discharge (A) recorded in a neuron in neocortical slices for (B) hNav1.1-WT, (C) hNav1.1-I236V, (D) hNav1.1-R1636Q, (E) hNav1.1-I1498T and (F) hNav1.1-I1498M. Scale bar = 20 ms. (G) Comparison of the current density of the first action current. (H) Comparison of the current density of the mean of the three last action currents. Data are shown as mean ± SEM.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 58 · Cited by 167

Metadata

Authors
Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., Delima, S., Gallois, J., Hanrahan, D., Lesca, G., MacLeod, S., Marjanovic, D., McTague, A., Nuñez-Enamorado, N., Perez-Palma, E., Scott Perry, M., Pysden, K., Russ-Hall, S. J., Scheffer, I. E., Sully, K., Syrbe, S., Vaher, U., Velayutham, M., Vogt, J., Weiss, S., Wirrell, E., Zuberi, S. M., Lal, D., Møller, R. S., Mantegazza, M., & Cestèle, S.
Affiliations
  • Royal Hospital for Children (GB)
  • University of Cologne (DE)
  • Instituto de Salud Carlos III (ES)
  • Kuopio University Hospital (FI)
  • Centre National de la Recherche Scientifique (FR)
  • ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology and Pediatric Neurology , Victor Babes, 43, 400012 Cluj-Napoca , Romania
  • Indiana University Health (US)
  • Louisiana State University (US)
  • Royal Belfast Hospital for Sick Children (GB)
  • Department of Medical Genetics, Lyon University Hospital, Member of the ERN EpiCARE , Université Claude Bernard Lyon 1, Lyon , France
  • The Danish Epilepsy Centre, Member of the ERN EpiCARE , Dianalund , Denmark
  • Great Ormond Street Hospital (GB)
  • Pediatric Neurology Department, 12 Octubre Universitary Hospital , Madrid , Spain
  • Universidad del Desarrollo, Centro de Genética y Genómica, Facultad de Medicina Clínica Alemana , Santiago , Chile
  • Jane and John Justin Neurosciences Center, Cook Children’s Medical Center , Ft Worth, TX , USA
  • Leeds General Infirmary (GB)
  • The University of Melbourne (AU)
  • Royal Children's Hospital (AU)
  • Baylor College of Medicine (US)
  • University Hospital Heidelberg (DE)
  • Tartu University Hospital (EE)
  • Birmingham Children's Hospital (GB)
  • Birmingham Women's Hospital (GB)
  • University of Toronto (CA)
  • Mayo Clinic (US)
  • Broad Institute (US)
  • University of Southern Denmark (DK)
Corresponding author
  • Brunklaus, Andreas
  • Møller, Rikke S
  • Mantegazza, Massimo
  • Cestèle, Sandrine
Venue
Brain
Published
2022-06-13
Volume
145
Issue
11
Pages
3816-3831
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4282598224
Cited by
167
References
58
Citations by year
2026: 36 · 2025: 54 · 2024: 40 · 2023: 29 · 2022: 8
FWCI
21.25
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • HAL (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc)
Funders
  • Dravet Syndrome Foundation (272016)
  • BMBF (01GM1907)
  • NIH
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
SCN1A, Nav1.1, gain-of-function mutations, Dravet syndrome, genetic epilepsy with febrile seizures plus, developmental and epileptic encephalopathy, arthrogryposis, movement disorders, sodium channel gating, persistent sodium current, neuronal hyperexcitability, sodium channel blockers, carbamazepine
MeSH terms
Epileptic Syndromes, Gain of Function Mutation, Arthrogryposis, Epilepsy, Epilepsies, Myoclonic, Humans, Infant, Infant, Newborn, Movement Disorders, Phenotype, Spasms, Infantile, Migraine with Aura, NAV1.1 Voltage-Gated Sodium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. https://app.cochat.ai/papers/10.1093/brain/awac210
The paper
Brunklaus, A., Brünger, T., Feng, T., Fons, C., Lehikoinen, A., Panagiotakaki, E., Vintan, M.-A., Symonds, J., Andrew, J., Arzimanoglou, A., Delima, S., Gallois, J., Hanrahan, D., Lesca, G., MacLeod, S., Marjanovic, D., McTague, A., Nuñez-Enamorado, N., Perez-Palma, E., . . . Cestèle, S. (2022). The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. https://doi.org/10.1093/brain/awac210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.